APA

Jasenosky L. D., Cadena C., Mire C. E., Borisevich V., Haridas V., Ranjbar S., Nambu A., Bavari S., Soloveva V., Sadukhan S., Cassell G. H., Geisbert T. W., Hur S. & Goldfeld A. E. (2019). The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. : iScience.

Chicago

Jasenosky Luke D, Cadena Cristhian, Mire Chad E, Borisevich Viktoriya, Haridas Viraga, Ranjbar Shahin, Nambu Aya, Bavari Sina, Soloveva Veronica, Sadukhan Supriya, Cassell Gail H, Geisbert Thomas W, Hur Sun and Goldfeld Anne E. 2019. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. : iScience.

Harvard

Jasenosky L. D., Cadena C., Mire C. E., Borisevich V., Haridas V., Ranjbar S., Nambu A., Bavari S., Soloveva V., Sadukhan S., Cassell G. H., Geisbert T. W., Hur S. and Goldfeld A. E. (2019). The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. : iScience.

MLA

Jasenosky Luke D, Cadena Cristhian, Mire Chad E, Borisevich Viktoriya, Haridas Viraga, Ranjbar Shahin, Nambu Aya, Bavari Sina, Soloveva Veronica, Sadukhan Supriya, Cassell Gail H, Geisbert Thomas W, Hur Sun and Goldfeld Anne E. The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus. : iScience. 2019.